Rebellions Accelerates Global Expansion and Strengthens Customer-centric Strategy with Significant Executive Appointments

Rebellions Appoints Industry Veteran Marshall Choy as Chief Business Officer to Drive Global Expansion

SEOUL, South Korea, Nov. 12, 2025 /PRNewswire/ -- Rebellions, Asia's fastest-growing AI inference chip company, today announced the appointment of Marshall Choy as Chief Business Officer. An industry veteran based in Silicon Valley with more than two decades of experience in enterprise systems and AI, Choy will lead Rebellions' newly established U.S entity and global business including go-to-market initiatives to accelerate commercialization and market adoption of its AI inference solutions.

Choy's appointment to this new leadership role comes as Rebellions enters its next phase of global growth, expanding its presence in APAC, Middle East, and North America. He will lead organizations that are responsible for shaping strategic alliances and business models that connect Rebellions' cutting-edge technology with the world's growing demand for efficient and scalable AI infrastructure.

Choy brings over 20 years of experience and leadership in product strategy, go-to-market, and enterprise systems. At SambaNova Systems, he led global teams across product management, sales and marketing, most recently serving as Chief Customer Officer. Prior to SambaNova, he held senior leadership roles at Oracle and Sun Microsystems, including serving as Vice President of Systems Product Management and Solutions Engineering at Oracle, while he drove product and solutions strategy across hardware, software and cloud.

Additionally, Jennifer Glore has been appointed Executive Vice President of Product Management to lead alignment across Rebellions' development teams and end users to drive delivery of customer-centric products and solutions. Glore has a proven track record of building high-performance teams and delivering customer-focused products and solutions across diverse and complex global markets.

As part of this expansion, Rebellions has officially opened its U.S. entity. The new entity will serve as the company's North American hub, focusing on business development, strategic partnerships, and customer engagement. Choy will lead Rebellions' initiatives in the U.S market to strengthen the company's presence and build long-term customer relationships in the region.

"We are delighted to welcome Marshall Choy and Jennifer Glore to Rebellions as we take the next step in our global expansion," said Sunghyun Park, CEO of Rebellions. "With our recent global funding success and partnerships with leading technology players, our Chief Business Officer, Marshall Choy's deep expertise in AI infrastructure and business strategy will make a significant impact as we scale globally, particularly as we strengthen our presence in the U.S. market"

"I am honored and excited to join Rebellions at this critical time in the company's growth, as they have become one of the most prominent AI innovators in the world," said Marshall Choy, Chief Business Officer of Rebellions. "Rebellions' strategic vision and thoughtful product philosophy deeply resonate with me, and I look forward to working with this winning team to expand its global presence to help shape the future of AI."

About Rebellions

Rebellions is an AI semiconductor and software company powering the next generation of large-scale inference. Building on the proven mass production and deployment of its first-generation ATOM, Rebellions now delivers energy-efficient AI infrastructure at scale with its flagship REBEL-Quad, featuring chiplet architecture and massive HBM3E memory paired with a flexible software stack that enables ease of use, performance, and efficiency in serving open source frontier and reasoning models at data center scale. Strengthened by strategic support from leaders across the semiconductor and AI infrastructure value chain, Rebellions is positioned to scale globally.

Visit us on the Web at Rebellions.ai, follow us on LinkedIn, engage us on X
Press Contact: Jeongin Kim jeongin.kim@rebellions.ai 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Rebellions Accelerates Global Expansion and Strengthens Customer-centric Strategy with Significant Executive Appointments

Rebellions Accelerates Global Expansion and Strengthens Customer-centric Strategy with Significant Executive Appointments

HOUSTON, May 14, 2026 /PRNewswire/ -- Elabscience^® Bionovation Inc. ("Elabscience^®" or "the Company") today announced the launch of its self-developed PolyHRP-Streptavidin conjugate, a signal amplification reagent designed to improve enzyme-linked immunosorbent assay (ELISA) sensitivity for low-abundance biomarker detection. Using proprietary covalent polymerization technology, the reagent creates a one-to-many amplification structure that strengthens detection signals while maintaining low background interference.

Elabscience^® developed its PolyHRP-Streptavidin conjugate to address a common ELISA challenge in which very low biomarker concentrations can make it difficult to increase signal output without also raising background noise. The product is built on a proprietary covalent coupling technique designed to create a more efficient amplification structure than traditional Streptavidin-HRP conjugates. In this process, a large number of highly active HRP enzymes are first polymerized to form a PolyHRP backbone, which is then conjugated to streptavidin. This one-to-many architecture increases the enzyme-to-protein ratio and enables cascade signal amplification which helps to improve assay sensitivity in low-abundance biomarker detection.

Dr. Yang Fei, General Manager of Elabscience^®, commented: "Sensitivity and stability are critical requirements in ELISA reagent development, especially when researchers are working with low-abundance targets. With our self-developed PolyHRP-Streptavidin conjugate, we aim to provide researchers and assay developers with a reliable signal amplification tool that supports stronger detection performance, lower background interference and long-term reagent stability."

Validation data showed strong performance across several key measures. SEC-HPLC analysis of three independent batches demonstrated an approximately 90% product recovery rate, with a peak area coefficient of variation of 2.9%, indicating high batch-to-batch consistency. Nanoparticle tracking analysis also showed a narrow particle size distribution centered at about 155 nm which supports the uniformity of the PolyHRP-Streptavidin polymer structure.

In internal performance testing, Elabscience^® PolyHRP-Streptavidin delivered strong signal intensity while maintaining low background signal. Accelerated stability testing at 37°C showed over 90% remaining activity after 11 days, demonstrating strong reagent stability under accelerated conditions. The product is also designed for broad compatibility across standard ELISA, high-sensitivity ELISA and competitive ELISA workflows.

The launch introduces Elabscience^® PolyHRP-Streptavidin conjugate, Catalog No. E-ELIR-020, as a specialized ELISA accessory reagent within the Company's signal amplification portfolio. It is available in a 50 μL trial size, a 250 μL catalog format, and custom volumes above 1 mL. The product is stored at -20°C and has a shelf life of two years. Elabscience^® also plans to introduce a ready-to-use PolyHRP-Streptavidin detection reagent to further support routine and high-throughput ELISA applications.

About Elabscience^® Bionovation Inc.      

Elabscience^® Bionovation Inc. is a biotechnology company focused on the design, development, manufacturing, and sale of research reagents and services for cell detection and life sciences applications. Its portfolio includes products for protein detection, immunoassays, metabolism analysis, and cell function research. Founded in 2011, Elabscience^® serves customers in more than 150 countries and regions. For more information, please visit www.elabscience.com, and connect with us on LinkedIn, YouTube, Facebook and Instagram.

Contact Information:
Elabscience^® Bionovation Inc
info@elabscience.com 
1-888-852-8623  

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Elabscience® Launches Self-Developed PolyHRP-Streptavidin Conjugate for Low-Abundance Biomarker Detection in ELISA